title: Lysosomal activity of pulmonary alveolar macrophages in acute experimental pancreatitis in rats with reference to positive PAF-antagonist (BN 52021) effect.
abstract: The activation of pulmonary alveolar macrophages (PAM's), might play an important role in severe complications of acute pancreatitis. The aim of our study was to assess the labilization of macrophage lysosomal membranes and release of lysosomal cathepsin B (CB) and N-acetyl-beta-D-hexosaminidase (NAH) into bronchoalveolar lavage fluid (BALF) during taurocholate acute pancreatitis (AP) in rats treated with PAF-antagonist--BN 52021. Total activity of CB increased by 374% after 6 h and by 237% after 12 h of AP in lysosomal enriched fraction of PAM's. Fractional free activity of CB increased to 40% after 6 h and to 38% after 12 h of AP. Free activity of CB was increased 5 fold in the supernatant of macrophage homogenate, and 10 fold in the supernatant of BALF after 6 h of AP. The values of NAH activity roughly paralleled that of CB. Treatment with BN 52021 (5 mg x kg(-1) every 6 h i.v.) partially normalized the measured parameters. Our results indicate that the PAF-antagonist BN 52021 reduced the increase of total and free activity of lysosomal hydrolases of PAM's and partly prevented the labilization of their lysosomal membranes. Therefore, an important mechanism of BN 52021 beneficial effect in pulmonary complications of acute pancreatitis could be dependent on the stabilization of PAM's lysosomes.
authors.affiliation: Department of Gastroenterology, University Medical School, Bialystok, Poland.
authors.forename: U
authors.initials: U
authors.lastname: Wereszczynska-Siemiatkowska
authors.forename: J W
authors.initials: JW
authors.lastname: Dlugosz
authors.forename: A
authors.initials: A
authors.lastname: Siemiatkowski
authors.forename: L
authors.initials: L
authors.lastname: Chyczewski
authors.forename: A
authors.initials: A
authors.lastname: Gabryelewicz
mesh_terms: D000208:Acute Disease; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D002401:Cathepsin B / Q000378:metabolism; D004224:Diterpenes; D046934:Ginkgolides; D007783:Lactones / Q000494:pharmacology*; D008214:Lymphocytes / Q000473:pathology; D008247:Lysosomes / Q000201:enzymology*; D016676:Macrophages, Alveolar / Q000648:ultrastructure*; D008297:Male; D009504:Neutrophils / Q000473:pathology; D010195:Pancreatitis / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D051381:Rats; D017208:Rats, Wistar; D013656:Taurocholic Acid; D001619:beta-N-Acetylhexosaminidases / Q000378:metabolism
chemical_list: D004224:Diterpenes; D046934:Ginkgolides; D007783:Lactones; D010972:Platelet Activating Factor; D013656:Taurocholic Acid; C045856:ginkgolide B; D001619:beta-N-Acetylhexosaminidases; D002401:Cathepsin B